Replies to post #38466 on Avid Bioservices Inc (CDMO)

[flglf4]

Abe, I totally agree. I've always felt this technology was underexploited - if it's as effective as it appears. There's definitely a need and it seems the company could get it to market much more easily, much quicker, and much cheaper as a diagnostic than a medication. Now that they have the patent, maybe they can find a way to get it moving quickly.

[jessme]

is it possible that this patent sets up the most immediate opportunity for commercialization as a diagnostic property rather than a medication?


Schering licensed VTA for imaging over 6 years ago. I don't see where it's expedited anything being a diagnostic rather than a therapeutic study.

Schering AG - Vascular Targeting Agents for nuclear imaging.
TUSTIN, Calif., Jan. 6 2003 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) has granted a worldwide exclusive license for the development of diagnostic and imaging agents in the field of oncology to Schering AG, Germany (Frankfurt: SCH)(NYSE: SHR). Under the terms of the agreement, Schering will have the exclusive right to develop and commercialize VTA based imaging and diagnostic agents for oncology. Financial terms of the agreement were not disclosed.